161 related articles for article (PubMed ID: 11585336)
1. Cathepsin K, osteoclastic resorption, and osteoporosis therapy.
Zaidi M; Troen B; Moonga BS; Abe E
J Bone Miner Res; 2001 Oct; 16(10):1747-9. PubMed ID: 11585336
[No Abstract] [Full Text] [Related]
2. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
[TBL] [Abstract][Full Text] [Related]
3. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone.
Everts V; Korper W; Hoeben KA; Jansen ID; Bromme D; Cleutjens KB; Heeneman S; Peters C; Reinheckel T; Saftig P; Beertsen W
J Bone Miner Res; 2006 Sep; 21(9):1399-408. PubMed ID: 16939398
[TBL] [Abstract][Full Text] [Related]
4. 6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents.
Deaton DN; Kumar S
Prog Med Chem; 2004; 42():245-375. PubMed ID: 15003723
[No Abstract] [Full Text] [Related]
5. Cystatin B as an intracellular modulator of bone resorption.
Laitala-Leinonen T; Rinne R; Saukko P; Väänänen HK; Rinne A
Matrix Biol; 2006 Apr; 25(3):149-57. PubMed ID: 16321512
[TBL] [Abstract][Full Text] [Related]
6. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones.
Xia L; Kilb J; Wex H; Li Z; Lipyansky A; Breuil V; Stein L; Palmer JT; Dempster DW; Brömme D
Biol Chem; 1999 Jun; 380(6):679-87. PubMed ID: 10430032
[TBL] [Abstract][Full Text] [Related]
7. Different cysteine proteinases involved in bone resorption and osteoclast formation.
Brage M; Abrahamson M; Lindström V; Grubb A; Lerner UH
Calcif Tissue Int; 2005 Jun; 76(6):439-47. PubMed ID: 15906014
[TBL] [Abstract][Full Text] [Related]
8. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
Yasuda Y; Kaleta J; Brömme D
Adv Drug Deliv Rev; 2005 May; 57(7):973-93. PubMed ID: 15876399
[TBL] [Abstract][Full Text] [Related]
9. Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro.
James IE; Marquis RW; Blake SM; Hwang SM; Gress CJ; Ru Y; Zembryki D; Yamashita DS; McQueney MS; Tomaszek TA; Oh HJ; Gowen M; Veber DF; Lark MW
J Biol Chem; 2001 Apr; 276(15):11507-11. PubMed ID: 11148212
[TBL] [Abstract][Full Text] [Related]
10. Specific biological functions of vacuolar-type H(+)-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts.
Sahara T; Itoh K; Debari K; Sasaki T
Anat Rec A Discov Mol Cell Evol Biol; 2003 Feb; 270(2):152-61. PubMed ID: 12524690
[TBL] [Abstract][Full Text] [Related]
11. 5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.
Morley AD; Kenny PW; Burton B; Heald RA; Macfaul PA; Mullett J; Page K; Porres SS; Ribeiro LR; Smith P; Ward S; Wilkinson TJ
Bioorg Med Chem Lett; 2009 Mar; 19(6):1658-61. PubMed ID: 19231183
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin K inhibitors: a novel target for osteoporosis therapy.
Stoch SA; Wagner JA
Clin Pharmacol Ther; 2008 Jan; 83(1):172-6. PubMed ID: 18073778
[TBL] [Abstract][Full Text] [Related]
13. Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption.
Dodds RA; James IE; Rieman D; Ahern R; Hwang SM; Connor JR; Thompson SD; Veber DF; Drake FH; Holmes S; Lark MW; Gowen M
J Bone Miner Res; 2001 Mar; 16(3):478-86. PubMed ID: 11277265
[TBL] [Abstract][Full Text] [Related]
14. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
[TBL] [Abstract][Full Text] [Related]
15. Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo.
Katunuma N; Matsui A; Inubushi T; Murata E; Kakegawa H; Ohba Y; Turk D; Turk V; Tada Y; Asao T
Biochem Biophys Res Commun; 2000 Jan; 267(3):850-4. PubMed ID: 10673380
[TBL] [Abstract][Full Text] [Related]
16. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in cathepsin K inhibitor design.
Grabowskal U; Chambers TJ; Shiroo M
Curr Opin Drug Discov Devel; 2005 Sep; 8(5):619-30. PubMed ID: 16159024
[TBL] [Abstract][Full Text] [Related]
18. Effects of an inhibitor of cathepsin L on bone resorption in thyroparathyroidectomized and ovariectomized rats.
Millest AJ; Breen SA; Loveday BE; Clarkson PN; Simpson CA; Waterton JC; Johnstone D
Bone; 1997 May; 20(5):465-71. PubMed ID: 9145244
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis.
Wang D; Li W; Pechar M; Kopecková P; Brömme D; Kopecek J
Int J Pharm; 2004 Jun; 277(1-2):73-9. PubMed ID: 15158970
[TBL] [Abstract][Full Text] [Related]
20. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
